Empagliflozin in Patients With Heart Failure Efficacy and Safety Concerns Across Kidney Risk Categories

被引：0
|
作者：
Ohshiro, Yuzuru [1 ]
机构：
[1] Omoromachi Med Ctr, Dept Internal Med, Uenoya 1-3-1, Naha, Okinawa 9010011, Japan
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 82卷 / 15期
关键词：
D O I：
10.1016/j.jacc.2023.06.052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E133 / E133
页数：1
相关论文
共 50 条
  • [31] Empagliflozin improves not only Heart Failure but also Kidney Function
    Lichert, Frank
    AKTUELLE KARDIOLOGIE, 2021, 10 (03) : 180 - 182
  • [32] Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo
    Tesfaye, Helen
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Jawaid, Dureshahwar
    Wexler, Deborah J.
    Glynn, Robert
    Koeneman, Lisette
    Luyet, Anouk Deruaz
    Paik, Julie
    Patorno, Elisabetta
    CIRCULATION, 2021, 144
  • [33] Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial
    Sharma, Abhinav
    Ferreira, Joao Pedro
    Zannad, Faiez
    Pocock, Stuart J.
    Filippatos, Gerasimos
    Pfarr, Egon
    Petrini, Michaela
    Kraus, Bettina J.
    Wanner, Christoph
    Packer, Milton
    Butler, Javed
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, : 1337 - 1348
  • [34] Empagliflozin and heart failure risk after myocardial infarction
    Di Lellis, Maddalena Angela
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (21) : 1257 - 1258
  • [35] Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure
    Yan, Crystal Lihong
    Gallo, Ryan A.
    Martinez, Moises Vasquez
    Rodriguez, Beatriz Rivera
    Trujillo, Luis
    Rivera, Nina Thakkar
    Hoffman, James E.
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 204 : 360 - 365
  • [36] Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease
    Uemura, Yusuke
    Shibata, Rei
    Takemoto, Kenji
    Uchikawa, Tomohiro
    Koyasu, Masayoshi
    Ishikawa, Shinji
    Imai, Ryo
    Ozaki, Yuta
    Watanabe, Takashi
    Teraoka, Tsubasa
    Watarai, Masato
    Murohara, Toyoaki
    CIRCULATION JOURNAL, 2017, 81 (11) : 1736 - +
  • [37] Empagliflozin and the risk of heart failure hospitalisation in routine clinical care: An interim analysis from the EMPagliflozin compaRative EffectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Bartels, D. B.
    Gopalakrishnan, C.
    Kulldorff, M.
    Schneeweiss, S.
    DIABETIC MEDICINE, 2019, 36 : 47 - 47
  • [38] Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
    Packer, Milton
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brunner-La Rocca, Hans-Peter
    Janssens, Stefan
    Tsutsui, Hiroyuki
    Zhang, Jian
    Brueckmann, Martina
    Jamal, Waheed
    Cotton, Daniel
    Iwata, Tomoko
    Schnee, Janet
    Zannad, Faiez
    EUROPEAN HEART JOURNAL, 2021, 42 (06) : 671 - 680
  • [39] Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bartels, Dorothee
    Gopalakrishnan, Chandrasekar
    Kulldorff, Martin
    Schneeweiss, Sebastian
    CIRCULATION, 2018, 138
  • [40] Safety and Efficacy of Cryoballoon Ablation in Patients With Congestive Heart Failure
    Tseng, Roger
    Al-Zubaidi, Muhanad
    Homer, Alexander
    DanCanay, Kelly
    Su, Wilber
    CIRCULATION, 2015, 132
12345